Dr. Bishop leads a research group focusing on how brain plasticity in the diseased brain, especially Parkinson's disease, may provide novel targets for improved treatment. His preclinical investigations into the role of 5-HT in L-DOPA-induced dyskinesia have informed several current translational targets in the clinical population. 

Collaboration: anti-dyskinetic activity of serotonin 5-HT1A receptor ‘biased’ agonists.


Binghamton University, The State University of New York


Follow Neurolixis on: